InChIKey	PQXKDMSYBGKCJA-CVTJIBDQSA-N
Compound Name	Lurasidone
Canonical SMILES	O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1
Clinical Status	Data-mined Candidate
Targets (Human+Pathogen)	5
Pfam Stratification	Homologous
Avg pChEMBL	8.89
Source	BindingDB;ChEMBL

DrugBank ID	DB08815
Drug Name	Lurasidone
CAS Number	367514-87-2
Groups	approved investigational
ATC Codes	N05AE05
Description	Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States.

---

Categories: Adrenergic Agents Adrenergic Antagonists Adrenergic alpha-2 Receptor Antagonists Adrenergic alpha-Antagonists Agents that produce hypertension Antidepressive Agents Antipsychotic Agents Antipsychotic Agents (Second Generation [Atypical]) Central Nervous System Agents Central Nervous System Depressants Cytochrome P-450 CYP3A Substrates Cytochrome P-450 CYP3A4 Substrates Cytochrome P-450 Substrates Dopamine Agents Dopamine Antagonists Dopamine D2 Receptor Antagonists Heterocyclic Compounds, Fused-Ring Hyperglycemia-Associated Agents Indole Derivatives Isoindoles Nervous System Neurotoxic agents Neurotransmitter Agents Potential QTc-Prolonging Agents Psycholeptics Psychotropic Drugs QTc Prolonging Agents Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome Serotonin 5-HT1 Receptor Antagonists Serotonin 5-HT1A Receptor Antagonists Serotonin 5-HT2 Receptor Antagonists Serotonin 5-HT2A Receptor Antagonists Serotonin Agents Serotonin Receptor Antagonists Sulfur Compounds Thiazoles Tranquilizing Agents

---

Cross-references: BindingDB: 85222 ChEBI: 70735 CHEMBL1237021 ChemSpider: 184739 Drugs Product Database (DPD): 21372 D04820 PharmGKB: PA166129557 PubChem:213046 PubChem:175427100 RxCUI: 1040028 Wikipedia: Lurasidone ZINC: ZINC000003927822